Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.
Jonathan Ratner, PhD
Advertisement
Articles by Jonathan Ratner, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
DOJ Abandons Olmstead Defense as Texas v Kennedy Advances
3
Midsized Biotechs Strike MFN Drug Pricing Deals
4
Myasthenia Gravis Linked to Greater Longevity Than Multiple Sclerosis
5